Investigator-Initiated Trials (IITs) represent a critical pathway for independent clinical research, enabling physicians and academic institutions to explore novel therapeutic hypotheses, expand indications for existing radiopharmaceuticals, and generate publishable evidence outside the scope of industry-sponsored programs. At Protheragen, we provide end-to-end IIT regulatory filing services that transform investigator-led research concepts into regulator-approved clinical trials, navigating the complex landscape of IND/CTA submissions, ethics approvals, and multi-jurisdictional compliance with precision and expertise.
Radioactive drug investigator-initiated trial registration demands careful preparation, regulatory expertise and multi-party coordination. Regional application rules and review cycles differ greatly, requiring extra radiation dosimetry, radioactive material operation and safety monitoring documents. Ethical approval for trial schemes and consent forms is required beforehand, with radiation risk reminders added to consent papers. Various official forms, trial registration and independent documents for each trial site must be finished, and multi-center trials raise ethical coordination difficulty. Lead researchers oversee trial implementation and compliance together. Combined pharmaceutical regulation, radiation safety and nuclear medical licensing rules bring heavy compliance pressure for academic researchers running such trials without professional assistance.
Fig 1. Comparison of patient enrollment between IIT and IND. (Yang, Yifan, et al., 2025)
| Topic | Key Information |
|---|---|
| Alpha-Emitter Pipeline | Actinium-225 (Ac-225) dominates with 20+ active trials. Several programs have reached Phase III, including RYZ101 for NET. Lead-212 and Astatine-211 are advancing in early-phase studies for glioblastoma and micrometastatic disease. |
| Beta-Emitter Standards | Lutetium-177 (Lu-177) remains the backbone, with approved agents Pluvicto and Lutathera driving label expansion. Copper-67 (Cu-67) is emerging as a theranostic pair with Cu-64 for both imaging and therapy. |
| Theranostics Paradigm | Paired diagnostic-therapeutic approach is now standard-of-care. Ga-68 PSMA-11 imaging + Lu-177 PSMA-617 therapy exemplifies this model, enabling patient selection, treatment monitoring, and response assessment. |
| Novel Targets | Beyond PSMA and SSTR, emerging targets include FAP, STEAP1, CD46, GRPR, DLL3, B7-H3, and TROP2, expanding applications to lung, brain, and GI malignancies. |
| Combination Strategies | Tandem alpha-beta therapy, combination with immune checkpoint inhibitors (PD-1/PD-L1), and PARP inhibitor pairings are under active investigation to overcome resistance and enhance efficacy. |
| IIT Growth in China | China is emerging as a leading IIT destination with lower costs, large patient populations, and streamlined ethics review timelines (4-8 months). High-quality IIT data can support IND submission and licensing decisions. |
| Regulatory Harmonization | ICH E6(R3) GCP (Sept 2025) and ICH M11 CeSHarP (May 2026) standardize protocol structure and electronic exchange across FDA, EMA, PMDA, and NMPA, reducing regional submission burden. |
| M&A Activity | Major acquisitions include BMS-RayzeBio ($4.1B), AstraZeneca-Fusion ($2.4B), and Novartis-Mariana ($1.75B), reflecting big pharma's strategic commitment to radiopharmaceutical platforms. |
| Isotope Supply Crunch | Ac-225 supply constraints have caused Phase III enrollment pauses even for major pharma. New production facilities (BMS Indianapolis, Novartis Carlsbad, Orano Med France) are addressing capacity gaps. |
| Trial Phase Distribution | Phase 2 studies account for the largest proportion (38%), followed by Phase 1 (29%) and Phase 1-2 (14%). Only 10% have reached Phase 3, indicating the field remains predominantly early-stage. |
Protheragen delivers comprehensive IIT regulatory filing services designed to navigate the complex intersection of radiopharmaceutical development and global regulatory requirements. Our integrated team of regulatory strategists, medical writers, and clinical operations specialists manages every aspect of the filing process—from IND/CTA preparation and submission to IRB/IEC coordination and ongoing regulatory maintenance—ensuring that investigator-led research programs advance efficiently from concept to clinical execution. Whether your IIT involves a novel alpha-emitter therapy, an established beta-emitter radioligand, or a pioneering theranostic pair, Protheragen provides the regulatory expertise and operational infrastructure to secure timely approvals and maintain compliance across all jurisdictions.
Full-set trial application dossier compilation and formal formatting delivery, covering preclinical research summaries, pharmaceutical production quality records, clinical trial schemes and researcher profile materials adapted to standard electronic submission formats.
Customized optimal regulatory route planning for investigator-initiated trials, including exemption qualification judgment, shared application based on existing sponsor trial approvals, and confirmation on radioactive drug committee supervision necessity. We formulate cross-region filing plans for global trial deployment.
Compile and dynamically update trial investigator manuals exclusive to radiopharmaceutical trials, integrating radiation dose measurement results, radionuclide attenuation features, handling specifications and overall safety profiles, with iterative revisions to match latest preclinical and clinical research outcomes.
Full-process ethical review application management for single-center and multi-center trials, covering trial scheme abstract drafting, radiation risk highlighted informed consent documents and safety archive collation. Coordinate centralized and decentralized ethical review mechanisms and reply to review comments efficiently.
Unified management of regulatory documents for all trial centers, prepare exclusive certification documents for each research site, submit local ethical materials and unify trial protocol versions to realize consistent compliance management across all research institutions.
Formulate safety monitoring frameworks and severe adverse event reporting procedures complying with international unified standards. Manage regular safety reports and unexpected adverse event submissions for radiopharmaceutical trials, and coordinate safety monitoring committee work focused on radiation-related adverse reactions.
Protheragen distinguishes itself as a specialized radiopharmaceutical CRDMO and CRO partner with deep expertise in the unique regulatory challenges of investigator-initiated trials. Our integrated platform combines regulatory strategy, clinical operations, and manufacturing capabilities to deliver seamless, end-to-end support for IIT programs.
Ready to advance your investigator-initiated radiopharmaceutical trial through the regulatory pathway with confidence? Contact us today to discuss your IIT regulatory filing needs. Our team of radiopharmaceutical regulatory specialists is prepared to guide you from pathway assessment through agency approval, ensuring that your independent research program meets the highest standards of scientific rigor and regulatory compliance.
Reference